Elsevier

Human Pathology

Volume 27, Issue 4, April 1996, Pages 381-388
Human Pathology

Original contribution
Proliferative activities in conventional chordoma: A Clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia

https://doi.org/10.1016/S0046-8177(96)90112-4Get rights and content

Abstract

Chordoma shows various degrees of atypia histologically, however, the relationship between the histological features and the biological behavior still remains controversial. The authors subclassified 17 specimens with chordoma into two groups (ie, trabecular type showing a trabecular pattern and solid type mainly consisting of a diffuse proliferation of tumor cells). The histological grading was performed according to the degree of nuclear atypia on a scale of 1 to 3. Using DNA flow cytometric and immunohistochemical techniques, both the proliferative index (% S + G2 + M phase) and the MIB-1 labeling index (LI) of the tumor cells were estimated regarding their proliferative activities. In addition, p53 overexpression was also investigated using immunohistochemical techniques. There were eight (47.1%) specimens of trabecular type and nine (52.9%) of solid type. In nine specimens of solid type, those with higher nuclear atypia (grade 2 or 3) were significantly more frequent (five specimens, 55.6%) than in trabecular type in which all of the eight specimens were grade 1 (P = .044). The proliferative index was significantly higher in grade 2 or 3 lesions than in grade 1 lesions (P = .014), and the MIB-1 LI tended to be higher in solid type than in trabecular type (P = .088). p53 overexpression was detected in two specimens of solid type, and the MIB-1 LI in these two specimens was significantly higher (P = .037) than that in the specimens without p53 overexpression. It was considered that the preceding anaplastic histological features, including either diffuse proliferation or high grade nuclear atypia, together with p53 overexpression, were thus closely related to the proliferative activities in chordomas.

References (57)

  • N Weidner et al.

    Correlation of KI-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel “paraffin”-reactive MIB1 antibody

    Hum Pathol

    (1994)
  • DC Dahlin et al.

    Chordoma: A study of fifty-nine cases

    Cancer

    (1952)
  • NL Higinbotham et al.

    Chordoma: Thirty-five-year study at Memorial Hospital

    Cancer

    (1967)
  • JM Heffelfinger et al.

    Chordomas and cartilaginuos tumors at the skull base

    Cancer

    (1973)
  • R Volpe et al.

    A clinicopathologic review of 25 cases of chordoma: A pleomorphic and metastasizing neoplasm

    Am J Surg Pathol

    (1983)
  • TA Rich et al.

    Clinical and pathologic review of 48 cases of chordoma

    (1985)
  • JM Heaton et al.

    Reflections on notochordal differentiation arising from a study of chordomas

    Histopathology

    (1985)
  • F Gentil et al.

    Sacrococcygeal chordoma

    Ann Surg

    (1948)
  • PW Chambers et al.

    Chordoma: A clinicopathologic study of metastasis

    (1979)
  • B Eriksson et al.

    Chordoma: A clinicopathologic and prognostic study of a Swedish national series

    Acta Orthop Scand

    (1981)
  • J Smith et al.

    Sacrococcygeal chordoma: A clinicopathological study of 60 patients

    Skeletal Radiol

    (1987)
  • J Chalmers et al.

    A metastasizing chordoma

    J Bone Joint Surg [Br]

    (1960)
  • KK Wu et al.

    Chordoma of the atlas: A case report

    J Bone Joint Surg [Am]

    (1979)
  • ML Eisemann

    Sphenooccipital chordoma presenting as a nasopharyngeal mass: A case report

    Ann Otol Rhinol Laryngol

    (1980)
  • JM Meis et al.

    “Dedifferentiated” chordoma: A clinicopathologic and immunohistochemical study of three cases

    Am J Surg Pathol

    (1987)
  • TM Murad et al.

    Ultrastructure of a chordoma

    Cancer

    (1970)
  • JX O'Connell et al.

    Base of skull chordoma: A correlative study of histologic and clinical features of 62 cases

    Cancer

    (1994)
  • AE Rosenberg et al.

    Chondroid chordoma-a variant of chordoma: A morphological and immunohistochemical study

    Am J Clin Pathol

    (1994)
  • Y Kaneko et al.

    Chordoma in early childhood: A clinicopathological study

    Neurosurgery

    (1991)
  • B Schutte et al.

    Flow cytometric determination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue

    Cytometry

    (1985)
  • LL Vindelov et al.

    A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis

    Cytometry

    (1983)
  • L Debernardi

    Cordomo sarcomatose del sacro

    Arch Sci Med (Torino)

    (1913)
  • L Bernard et al.

    Les chordomes de la region sacrococcygienne et leur histogenese

    Bull Cancer (Paris)

    (1922)
  • C Davison et al.

    Malignant chordoma of the lumbar region

    Arch Neurol Psychiatry

    (1928)
  • RE Mabrey

    Chordoma: A study of 150 cases

    Am J Cancer

    (1935)
  • W Harvey et al.

    Chordoma

    Edinburgh Med J

    (1941)
  • JL Poppen et al.

    Chordoma: Experience with thirteen cases

    J Neurosurg

    (1952)
  • Cited by (41)

    • The Degree of Middle and Lower Clivus Invasion by Chordoma is Linked to Patient Prognosis Via Ki-67 Value

      2019, World Neurosurgery
      Citation Excerpt :

      Additional factors related to the chordoma prognosis have been reported in previous studies, including the growth and invasion site of the tumor, the deletion and acquisition of genes, and the misregulation of related genes. The proliferative ability of skull-base chordomas seems to be closely related to recurrence and nuclear pleomorphism,20 and correlates with the combination of p53 overexpression, abnormal proliferation, high heteromorphism, and diffuse proliferation.21 Mutation of p53 can also lead to an increased probability of recurrence.

    • Recurrent skull base chordomas: Role of surgery

      2018, Chordomas and Chondrosarcomas of the Skull Base and Spine
    • Pathology of chordoma and chondrosarcoma of the axial skeleton

      2018, Chordomas and Chondrosarcomas of the Skull Base and Spine
    • Chordoma: The entity

      2014, Biochimica et Biophysica Acta - Reviews on Cancer
      Citation Excerpt :

      DNA sequencing of the full p53 gene would clarify such ambiguity, but to date has not been reported. However, data concerning p53 protein overexpression are available but varying expression has been reported between 0% and 53% [117,122–127]. Even though all of the studies are based on immohistochemical techniques, the discrepancy in outcome might be explained by the use of semi-qualitative versus quantitative methods of analysis, and by differences in interpretations (cut-off points) of the data.

    • A Comparison of Cell-Cycle Markers in Skull Base and Sacral Chordomas

      2014, World Neurosurgery
      Citation Excerpt :

      MDM2 expression is also controlled by p53 transcription, making it a negative feedback regulatory system (22). In chordoma, inconsistent p53 overexpression has been reported by several authors (15, 18, 23, 28, 30, 33, 37), but is shown to be well correlated with a high MIB-1 labeling index (LI), a proliferation index using the expression of the Ki-67 protein (23, 28, 30, 33, 37). Excess p53 protein, in addition, generally is associated with a worse clinical outcome.

    • Skull Base Chordomas. Clinical Features, Prognostic Factors, and Therapeutics.

      2013, Neurosurgery Clinics of North America
      Citation Excerpt :

      Other factors believed to influence prognosis include the classic and chondroid histology (better prognosis compared with dedifferentiated variant), the presence of necrosis and mitotic figures (poor prognosis), metastases (poor prognosis), larger tumor volume at diagnosis (prognostic factor for tumor recurrence and poor prognosis), and Ki67-positive staining (poor prognosis).5,7,102 Additional molecular expression marker studies have identified MIB-I, p53, and cyclin D1 as potential predictors of recurrence and prognosis, citing that the proliferative potential of chordomas may be correlated with the combination of p53 overexpression, anaplasia, and high-grade atypia.103,104 Skull base chordomas are exceptionally rare tumors that grow in the clivus, often presenting with CN palsies, headache, and visual field cuts.

    View all citing articles on Scopus

    Supported in part by Grants in Aid for Scientific Research (grant nos. 06280105 and 06280115) from the Ministry of Education, Science and Culture, Japan.

    View full text